Kåre Engkilde - CEO since 2019

Kåre Engkilde

CEO since 2019

Kåre Engkilde (born 1977) holds a PhD in Health Science from the University of Copenhagen and a Master of Science in Chemistry and Biotechnology from the Danish Institute of Technology. Kåre Engkilde has more than a decade of experience in the pharmaceutical industry, including Senior researcher at Gentofte University Hospital and Rigshospitalet University Hospital in Copenhagen and Danish Diabetes Academy in Denmark. He also served as Senior Scientist and Team Leader respectively at the global healthcare companies Novo Nordisk and LEO Pharma. Kåre Engkilde has experience as head of development and head of the immunology group at Bioneer A/S and has at Agilent Technologies been heading the global Medical & Clinical Affairs Department. Kåre Engkilde has written nearly 30 scientific articles, and is an inventor of a number of patents. Furthermore, he has held several lectures and academic presentation e.g. at ESCD (The European Society of Contact Dermatitis) Congress and the European Association for the Study of Diabetes. Kåre Engkilde is also a member of the Danish Society of Immunology and the Danish Society of Flow Cytometry.

Holdings in the company: 22 000 shares and 1 100 warrants series 2020/2023

Johny Humaloja - CFO since 2021

Johny Humaloja

CFO since 2021

Johny Humaloja (born 1966) has a degree in economics and an MBA from Lund University. Johny Humaloja has over 25 years of experience in financial management and leadership, primarily in global Life Science companies. Among other things, Johny Humaloja was involved in starting up Biogen’s commercial operations in the Nordic region, and worked internationally as CFO at Biogen’s large-scale production facility for the production of biological drugs in North Carolina, USA, with a focus on process economics and efficiency. Subsequently, Johny Humaloja was involved in setting up a similar production facility in Hilleröd, Denmark. Johny Humaloja has also worked as Nordic CFO at the Medtech company Boston Scientific and, among other things, contributed to the development of new business models and legal structures. Johny Humaloja was most recently CFO of the biotech company Genovis AB.

Holdings in the company: 64 675 employee options series 2021/2026

Jan Talts - COO since 2017

Jan Talts

COO since 2017

Jan Talts (born 1965) holds a PhD in Animal Physiology from Uppsala University and is an Associate Professor of Cell and Molecular Biology at Lund University Faculty of Medicine. Jan Talts has extensive R&D and management experience from academia, the biotechnology industry and the healthcare sector. Jan Talts has researched development and disease for over 30 years and has held positions as Research Associate at the Max-Planck-Institute for Biochemistry in Munich, Associate Professor and section leader for Anatomy and Cell biology at the University of Copenhagen, Medical Director in Clinical Pathology, Lund University Hospital and Senior Researcher, Project Manager and ECA Certified QA Manager at Xintela AB, a regenerative medicine company. Jan Talts is the inventor of several patents and has published articles in international journals such as Cell, Molecular Cell, EMBO J and PNAS. Jan Talts is well acquainted with most aspects of cell therapy development and has practical experience in pre-clinic, CMC and the regulatory field.

Holdings in the company: 72 000 shares, 300 warrants series 2020/2023 and 64 675 employee options series 2021/2026

Helle Størum - Head of Business Development since 2020

Helle Størum

Head of Business Development since 2020

Helle Størum (born 1967) holds a bachelor’s degree in business administration from the University of Southern Denmark and has over 20 years of international experience in the Life Science sector. Helle Størum has experience from leading positions in strategic marketing/portfolio management, corporate and business development in both large and medium-sized pharmaceutical companies, as well as small biotechnology companies. Helle Størum also has a strong track record in several aspects of business development; licensing, listing, financing and alliance management, and was involved in several deals with major pharmaceutical and biotechnology companies in the US, Europe and Australia. Helle Størum has been involved in the listing of H. Lundbeck and Zealand Pharma on the OMX Copenhagen Stock Exchange and the listing of Zealand Pharma on Nasdaq Stock Market (New York). Between 2008 and 2016, Helle Størum served as an employee-elected board member of Zealand Pharma for two subsequent periods.

Holdings in the company: 64 675 employee options series 2021/2026